-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing Pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...

-Down to Earth US actions jeopardise India's pro-poor patent laws that promote generic drugs production, says online global petition More than 75,000 people have requested Prime Minister Narendra Modi not to succumb to US pressure on Intellectual Property Rights (IP). With trade and intellectual property rights featuring prominently in the agenda of US president Barak Obama's India visit, civil society groups have expressed concern that talks on these issues are designed to make...

-Livemint.com   The interim injunction has been granted till Cipla's application for compulsory licensing of the drug is decided   New Delhi: The Delhi high court on Friday restrained homegrown generic drug maker Cipla Ltd from making and selling Indacaterol, a drug claimed to be patented by Swiss Pharma company Novartis AG. Indacaterol is a respiratory drug used in the treatment of chronic obstructive pulmonary disease and is sold under the brand name Onbrez. Please...

-Economic and Political Weekly The key to improving the quality of healthcare services in India and reducing costs at the same time can be found by enacting legislation which lays down minimum standards of patient care. In the absence of such standards and the reluctance of health insurance companies to standardise either price or quality, healthcare services continue to be expensive and of doubtful quality. Developing standards of patient care by...

-The Hindu New Delhi: While observing that the Court could not encroach into policy matters of the government, the Delhi High Court has dismissed a public interest writ petition seeking directions to the Centre to make available generic medicines and medical treatment to the public at large at a reasonable cost. A Division Bench comprising Chief Justice G. Rohini and Justice R.S. Endlaw had earlier this week said that the Centre and...